NCT01724086 / 2012-002555-42: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus |
|
|
| Completed | 2a | 90 | Europe | TMC647055, JNJ-42039556-AMR-G-001, TMC435, Ritonavir, Ribavirin, Pegylated interferon alpha-2a (PegIFN), GSK2336805 | Janssen R&D Ireland | Chronic Hepatitis C | 09/14 | 12/14 | | |
NCT01852604: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) |
|
|
| Completed | 2 | 143 | US | Samatasvir, Simeprevir, Ribavirin (RBV), TMC647055, Ritonavir (RTV), Pegylated interferon (Peg-IFN), Samatasvir matching placebo | Merck Sharp & Dohme LLC, Janssen Research & Development, LLC | Chronic Hepatitis C Virus | 04/15 | 04/15 | | |